Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Metagenomi Therapeutics (MGX): Analyst Targets Signal +914% Upside From Current Levels

Metagenomi Therapeutics (MGX): Analyst Targets Signal +914% Upside From Current Levels

Key Takeaways

  • The central stock price target is $7, the arithmetic mean of three current, identifiable analyst targets: Wells Fargo ($7), Chardan Capital ($5), and Jefferies ($9).
  • At a recent price near $0.69, reaching $7 would require a gain of roughly 914%, a very large move.
  • The analyst price target range of $5 to $9 is wide, reflecting genuine disagreement about a pre-revenue, clinical-stage biotech.
  • The strongest supports are the U.S. FDA's clearance of the MGX-001 investigational new drug (IND) application and a cash runway into 2028.
  • The biggest risks are declining collaboration revenue, ongoing net losses, and the absence of an approved or marketed product.
  • For more detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages for MGX.
  • Explore Trending AI Robots to see AI-driven trading strategies across the market.

Analyst Price Targets and Consensus View

Three individual, attributable analyst targets were reviewed. Wells Fargo's Yanan Zhu reiterated an Overweight (Buy) rating with a $7 target in November 2026, after lowering it from $9. Chardan Capital's Keay Nakae initiated coverage with a Buy and a $5 target. Jefferies carries a Buy with a $9 target. Averaging $5, $7, and $9 produces a mean of $7.00, consistent with the $7.00 average reported by S&P Global, which polls five analysts and shows a consensus "Strong Buy" with a low of $5 and a high of $9.

The spread between $5 and $9 underscores the binary nature of this story: analysts broadly agree the pipeline has value, but they differ on how much credit to give a program that has only just entered clinical development. Additional firms, including J.P. Morgan (Hold) and TD Cowen (Buy), maintain ratings without current published targets. The $7 figure is a calculated mean, not a guarantee or an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

The shares closed near $0.69 in mid-November 2026, giving the company a market capitalization of roughly $26 million. Moving to $7 would require about a 914% gain, a very large move by any standard. The 52-week range is $0.60 to $1.87, so even reclaiming the prior high would represent only a fraction of the distance to the target.

The theoretical path rests on clinical execution: the FDA cleared the IND for MGX-001, and the company plans to begin the global INTEGR8 Phase 1/2 trial in the first half of 2027, with initial safety and Factor VIII activity data expected in the second half of 2027. Notably, the company held about $101.7 million in cash and marketable securities at September 30, 2026, roughly $2.69 per share, meaning the stock trades well below its net cash per share. That mismatch is part of what underpins the elevated analyst targets, but it also reflects the market's skepticism about clinical-stage gene-editing risk. From what I see, this cash position provides a notable valuation anchor.

What Could Support a Move Toward the Target

  • The IND clearance removes a key near-term regulatory hurdle and de-risks MGX-001's advancement into human testing.
  • A cash runway into 2028 reduces, though does not eliminate, immediate financing overhang.
  • The stock trades below net cash, a valuation anchor that some analysts see as disconnected from the pipeline's optionality.
  • Preclinical data showing durable Factor VIII expression and no detectable off-target editing support the scientific thesis for a one-time hemophilia A therapy.
  • A "Strong Buy" analyst consensus and recent insider buying signal some institutional and insider confidence.

What Could Prevent the Target From Being Reached

  • Collaboration revenue fell to $2.2 million in the third quarter from $8.7 million a year earlier, and revenue overall is shrinking as partnerships wind down.
  • The company continues to post significant losses, including a $21.1 million net loss in the third quarter of 2026.
  • With no approved products, the stock's value hinges almost entirely on early-stage clinical data that could disappoint.
  • Future capital raises could dilute shareholders substantially at depressed prices.
  • The shares have fallen roughly 63% over the past year, and price targets may not yet reflect deteriorating sentiment.

Technical Levels and Market Structure

The stock has been in a pronounced downtrend. The 52-week low near $0.60 is the key support level to hold, while the $1.00 psychological level, the 50-day moving average near $0.95, and the 200-day moving average near $1.25 all sit above the current price as resistance. A durable recovery would likely need to reclaim $1.00 first, followed by the prior high near $1.87, before any move toward $7 could be contemplated.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, and the targets cited here appear consistent with that convention, though firms do not always state an explicit horizon. The most important catalysts are the initiation of the INTEGR8 trial in the first half of 2027, initial clinical data expected in the second half of 2027, the American Society of Hematology presentation in December 2026, quarterly cash-burn updates, and any changes to analyst ratings or targets. I’m watching this closely as those milestones approach.

Leveraging Tickeron’s AI Daily Buy/Sell Signals

In my view, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to monitor volatile names like MGX by generating data-driven Buy, Sell, or Hold signals based on technical behavior and market conditions. I have found these signals useful for complementing fundamental analysis on early-stage biotechs, helping spot shifts in momentum without replacing deeper due diligence. Traders can explore the tool to add an extra layer to their own research process.

Final Assessment

The question of whether MGX can reach $7 is best understood as a question about whether the company can successfully advance MGX-001 through early clinical trials. The $7 central target is the average of three analyst targets ranging from $5 to $9, implying a very large move of roughly 914% from a price near $0.69. Support comes from the FDA's IND clearance, a cash runway into 2028, and a stock price below net cash; the principal obstacles are shrinking collaboration revenue, persistent losses, and the inherent risk of early-stage gene editing. Investors should watch clinical initiation and data milestones, cash position, and analyst revisions, keeping in mind that a wide target range signals substantial uncertainty rather than a clear path.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MGX

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


MGX sees its Stochastic Oscillator ascending out of oversold territory

On November 06, 2026, the Stochastic Oscillator for MGX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 30 instances where the indicator left the oversold zone. In 26 of the 30 cases the stock moved higher in the following days. This puts the odds of a move higher at over 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MGX's RSI Oscillator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for MGX just turned positive on October 29, 2026. Looking at past instances where MGX's MACD turned positive, the stock continued to rise in 18 of 22 cases over the following month. The odds of a continued upward trend are 82%.

Following a +4.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGX advanced for three days, in 88 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

MGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for MGX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (3.195) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
5959 Horton Street
Phone
+1 510 871-4880
Employees
119
Web
https://metagenomi.co
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.